SAN DIEGO, Dec. 1, 2010 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision intravascular diagnosis and therapy guidance tools designed to enhance the treatment of coronary and peripheral vascular disease, said today that it will be participating in the 5th Annual Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference on Tuesday, December 7.
The presentation by John Dahldorf, chief financial officer, will begin at 11:30 a.m., Pacific Standard Time (2:30 p.m., Eastern Standard Time).
The presentation will be available through the conference website at http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=3298900 and via the company's website at www.volcanocorp.com.
Volcano Corporation is revolutionizing the medical device industry with a broad suite of technologies that make imaging and therapy simpler, more informative and less invasive. Our products empower physicians around the world with a new generation of analytical tools that deliver more meaningful information — using light and sound as the guiding elements. Founded in cardiovascular care and expanding into other specialties, Volcano is changing the assumption about what is possible in improving patient outcomes by combining imaging and therapy together. For more information, visit the company's website at www.volcanocorp.com.
SOURCE Volcano Corporation